Merck to Acquire Terns Pharmaceuticals in $6.7B Hematology Push
Key Takeaways
- Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment.
- The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Key Intelligence
Key Facts
- 1Merck will acquire Terns Pharmaceuticals for $6.7 billion in an all-cash transaction.
- 2The deal's primary asset is TERN-701, an oral allosteric BCR-ABL inhibitor for leukemia.
- 3Merck is seeking to offset revenue losses from the 2028 patent expiration of Keytruda.
- 4Keytruda currently generates approximately $25 billion in annual revenue for Merck.
- 5TERN-701 is designed to compete with established CML treatments like Novartis's Scemblix.
- 6The acquisition is expected to close in the second half of 2026, pending regulatory approval.
Who's Affected
Analysis
The $6.7 billion acquisition of Terns Pharmaceuticals marks a significant pivot for Merck (known as MSD outside the US and Canada) as it aggressively seeks to diversify its oncology portfolio. The centerpiece of the deal is TERN-701, an oral allosteric BCR-ABL tyrosine kinase inhibitor (TKI) currently in development for chronic myeloid leukemia (CML). This acquisition is not merely an expansion of Merck’s pipeline but a calculated defensive maneuver against one of the most significant financial hurdles in the pharmaceutical industry: the upcoming patent cliff for Keytruda.
Keytruda, Merck’s flagship cancer immunotherapy, has long been the world’s top-selling drug, generating over $25 billion in annual revenue. However, with key patents set to expire in 2028, Merck faces a massive revenue vacuum that could destabilize its market leadership if not addressed through high-impact acquisitions. By bringing Terns Pharmaceuticals into the fold, Merck is signaling its intent to become a dominant force in hematology, a sector where it has historically had a smaller footprint compared to its overwhelming dominance in solid tumors. TERN-701 represents a high-potential asset that could capture significant market share in the blood cancer space, particularly as it targets the same mechanism as Novartis’s successful Scemblix but with potentially superior clinical profiles.
The $6.7 billion acquisition of Terns Pharmaceuticals marks a significant pivot for Merck (known as MSD outside the US and Canada) as it aggressively seeks to diversify its oncology portfolio.
The biopharmaceutical industry is currently witnessing a resurgence in mid-sized acquisitions as large-cap players look to de-risk their pipelines by purchasing clinical-stage assets with proven mechanisms of action. Allosteric inhibitors like TERN-701 are considered the next frontier in CML treatment because they offer a more precise way to shut down the proteins that drive cancer growth, often with fewer side effects than traditional TKIs. For Merck, the $6.7 billion price tag reflects a premium for a drug that is already showing promise in early-to-mid-stage trials, reducing the binary risk often associated with early-stage biotech investments.
What to Watch
From a competitive standpoint, this deal places Merck in direct contention with Novartis and Bristol Myers Squibb, the traditional leaders in the CML market. Analysts suggest that Merck’s global commercial infrastructure and deep expertise in oncology clinical trials will accelerate the development of TERN-701, potentially bringing it to market faster than Terns could have achieved as a standalone entity. This "string of pearls" acquisition strategy—buying smaller, specialized companies to build a diversified portfolio—has become Merck’s primary tool for navigating the post-Keytruda era.
Looking ahead, the success of this deal will hinge on the upcoming Phase 2 and Phase 3 data for TERN-701. If the drug meets its primary endpoints for efficacy and safety, it could become a multi-billion dollar blockbuster in its own right. Investors will also be watching for further M&A activity from Merck, as the company still has a significant cash pile and a clear mandate to replace the revenue that will be lost at the end of the decade. This acquisition is a clear signal that Merck is willing to pay a premium for high-quality science that fits its long-term strategic vision of remaining the world’s premier oncology company.
From the Network
Merck to Acquire Terns for $6.7B to Fortify Oncology Pipeline
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio. The acquisition comes as Merck prepares
BiotechMerck to Acquire Terns for $6.7B to Mitigate Keytruda Patent Cliff
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leuke
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |